CTI BioPharma Corp. (NASDAQ:CTIC) and ImmunoCellular Therapeutics Ltd. (OTCMKTS:IMUC), both competing one another are Biotechnology companies. We will contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CTI BioPharma Corp.	26.29M	2.12	29.40M	-0.87	0.00
ImmunoCellular Therapeutics Ltd.	N/A	0.00	9.03M	-0.48	0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
CTI BioPharma Corp.	-111.83%	-77.4%	-49.1%
ImmunoCellular Therapeutics Ltd.	0.00%	-321.9%	-158.6%

Risk and Volatility

CTI BioPharma Corp. has a 1.59 beta, while its volatility is 59.00% which is more volatile than Standard and Poor’s 500. ImmunoCellular Therapeutics Ltd.’s -0.31 beta is the reason why it is 131.00% less volatile than Standard and Poor’s 500.

Liquidity

The current Quick Ratio of CTI BioPharma Corp. is 3.6 while its Current Ratio is 3.6. Meanwhile, ImmunoCellular Therapeutics Ltd. has a Current Ratio of 9.5 while its Quick Ratio is 9.5. ImmunoCellular Therapeutics Ltd. is better positioned to pay off its short-term and long-term debts than CTI BioPharma Corp.

Institutional and Insider Ownership

CTI BioPharma Corp. and ImmunoCellular Therapeutics Ltd. has shares held by institutional investors as follows: 61.1% and 4.3%. Insiders held roughly 0.1% of CTI BioPharma Corp.’s shares. Comparatively, ImmunoCellular Therapeutics Ltd. has 0.3% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
CTI BioPharma Corp.	21.23%	0%	-30.41%	-36.02%	-70.32%	62.21%
ImmunoCellular Therapeutics Ltd.	-4%	-11.11%	-25%	-90%	-91.04%	41.18%

For the past year CTI BioPharma Corp.’s stock price has bigger growth than ImmunoCellular Therapeutics Ltd.

Summary

CTI BioPharma Corp. beats on 5 of the 9 factors ImmunoCellular Therapeutics Ltd.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma multiforme (GBM). The company is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers. In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.